Literature DB >> 19172026

Diffuse hair loss in an adult female: approach to diagnosis and management.

Shyam Behari Shrivastava1.   

Abstract

Telogen effluvium (TE) is the most common cause of diffuse hair loss in adult females. TE, along with female pattern hair loss (FPHL) and chronic telogen effluvium (CTE), accounts for the majority of diffuse alopecia cases. Abrupt, rapid, generalized shedding of normal club hairs, 2-3 months after a triggering event like parturition, high fever, major surgery, etc. indicates TE, while gradual diffuse hair loss with thinning of central scalp/widening of central parting line/frontotemporal recession indicates FPHL. Excessive, alarming diffuse shedding coming from a normal looking head with plenty of hairs and without an obvious cause is the hallmark of CTE, which is a distinct entity different from TE and FPHL. Apart from complete blood count and routine urine examination, levels of serum ferritin and T3, T4, and TSH should be checked in all cases of diffuse hair loss without a discernable cause, as iron deficiency and thyroid hormone disorders are the two common conditions often associated with diffuse hair loss, and most of the time, there are no apparent clinical features to suggest them. CTE is often confused with FPHL and can be reliably differentiated from it through biopsy which shows a normal histology in CTE and miniaturization with significant reduction of terminal to vellus hair ratio (T:V < 4:1) in FPHL. Repeated assurance, support, and explanation that the condition represents excessive shedding and not the actual loss of hairs, and it does not lead to baldness, are the guiding principles toward management of TE as well as CTE. TE is self limited and resolves in 3-6 months if the trigger is removed or treated, while the prognosis of CTE is less certain and may take 3-10 years for spontaneous resolution. Topical minoxidil 2% with or without antiandrogens, finestride, hair prosthesis, hair cosmetics, and hair surgery are the therapeutically available options for FPHL management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19172026     DOI: 10.4103/0378-6323.45215

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  13 in total

Review 1.  Telogen Effluvium: A Review.

Authors:  Shashikant Malkud
Journal:  J Clin Diagn Res       Date:  2015-09-01

2.  A Hospital-based Study to Determine Causes of Diffuse Hair Loss in Women.

Authors:  Shashikant Malkud
Journal:  J Clin Diagn Res       Date:  2015-08-01

3.  A retrospective study of thyroid structural abnormalities in alopecia patients.

Authors:  Kristen Lo Sicco; Sean McGuire; Joseph C English
Journal:  Dermatoendocrinol       Date:  2011-10-01

4.  Serum ferritin and vitamin D levels should be evaluated in patients with diffuse hair loss prior to treatment.

Authors:  Funda Tamer; Mehmet Eren Yuksel; Yavuz Karabag
Journal:  Postepy Dermatol Alergol       Date:  2020-07-16       Impact factor: 1.837

5.  Clinicoepidemiological Observational Study of Acquired Alopecias in Females Correlating with Anemia and Thyroid Function.

Authors:  Kirti Deo; Yugal K Sharma; Meenakshi Wadhokar; Neha Tyagi
Journal:  Dermatol Res Pract       Date:  2016-01-20

6.  Preclinical and Clinical Studies Demonstrate That the Proprietary Herbal Extract DA-5512 Effectively Stimulates Hair Growth and Promotes Hair Health.

Authors:  Jae Young Yu; Biki Gupta; Hyoung Geun Park; Miwon Son; Joon-Ho Jun; Chul Soon Yong; Jeong Ah Kim; Jong Oh Kim
Journal:  Evid Based Complement Alternat Med       Date:  2017-04-30       Impact factor: 2.629

Review 7.  Telogen Effluvium: A Review of the Literature.

Authors:  Fahham Asghar; Nazia Shamim; Umar Farooque; Haris Sheikh; Ramsha Aqeel
Journal:  Cureus       Date:  2020-05-27

8.  Non-scarring Alopecias in Iranian Patients: A Histopathological Study With Hair Counts.

Authors:  Fatemeh Sari Aslani; Mina Heidari Esfahani; Mozhdeh Sepaskhah
Journal:  Iran J Pathol       Date:  2018-09-12

9.  Serum drug level-related sodium valproate-induced hair loss.

Authors:  Suresh K Ramakrishnappa; Mahesh N Belhekar
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

10.  Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management.

Authors:  Michela Starace; Matilde Iorizzo; Andrea Sechi; Aurora Maria Alessandrini; Miriam Carpanese; Francesca Bruni; Giulio Vara; Zoe Apalla; Daniel Asz-Sigall; Stefania Barruscotti; Francisco Camacho; Isabella Doche; Bruna Duque Estrada; Rachita Dhurat; Maria Fernanda Gavazzoni; Ramon Grimalt; Matthew Harries; Dimitrios Ioannidis; Amy McMichael; Daniel Fernandes Melo; Rui Oliveira; Yuliya Ovcharenko; Rodrigo Pirmez; Yuval Ramot; Lidia Rudnicka; Jerry Shapiro; Tatiana Silyuk; Rodney Sinclair; Antonella Tosti; Sergio Vano-Galvan; Bianca Maria Piraccini
Journal:  JAAD Int       Date:  2021-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.